American Academy of Ophthalmology

David, what are you

doing in Academy this year, and what do you look forward to hearing about?

So I'm skipping Retina Society this week.

It's my birthday on Friday, my 50th birthday.

I'm going to grow a gray beard overnight.

It's going to be awesome.

um uh so i'm not a retina society i am at eu retina i have got out abstract for oln324 the jade study at eu retina and i have kind of a fun proof of concept i did with ai and geographic atrophy lesions that i'm excited to present in europe for the first time with retina ai um at academy i've got uh i've got a boatload of uh cme work at academy um i've got Uh, no podium presentations at Academy.

I was denied my two podium applications because Academy is tough, man.

And it kind of leads into my column this month.

At the American Academy of Ophthalmology meeting, there was a ton of talk about AI and oculomics.

And the takeaway for me basically was the science is real.

The science is there.

Because when I first learned about it, I was kind of blown away.

And I recently gave a CME at Academy of Ophthalmology.

And, you know, the questions from the audience from a general ophthalmology standpoint were a little all over the place, indicating that there's a big educational gap here.

When we inject a medicine like 4D150, we are able to incorporate that into the retina cells and that those retina cells will produce a flipper set.

But what learnings from the dataset can inform our understanding of TKI's potential to address exudative disease? Stick with us to find out.

We've heard rumblings about the Wnt pathway's ability to mediate exudative disease activity, and at AAO subspecialty day this year, we heard data from the Brunello study, which was by far the largest data set exploring this potential.

The drug in question, Remigremig and the disease, DME.

Dr.

The Lugano and Lucia trials are assessing the safety and efficacy of the virolinib intravitreal insert, or Duravue, for the treatment of wet AMD.

The Lucia data are due out soon, but the Lugana data are in.

Dr. Carl Ogillo shared data from Lugano at AAO Retina Subspecialty Day, and he's on mic today to tell us more about it.

Dr. Ruggillo is the Director Emeritus of the Retina Service at Will's Eye Hospital and a partner at Mid-Atlantic Retina, both located in Philadelphia.

We're going to actually explore this a little bit more, specifically with RestoreIt and iBio.

When we come back from the break, we're going to speak with Don D'Amico, who delivered results from the Phase 3 Brunello study at AAO this year.

We're going to hear a little bit about the data, but really widen the aperture and see what he thinks about where this could fit into the entire retina landscape.

Stick with us.

Oh, thank you, Scott.

Pleasure to be here.

Don, it's always great to talk to you in any context, but I'll tell you, you probably gave the most anticipated talk of the AAO subspecialty day in 2026 down in New Orleans.

It was the phase three Brunello study results.

Now, here's your host.

Welcome to this podcast where we are going to discuss updates from Your Retina, the Retina Society, and the American Academy of Ophthalmology.

We're going to discuss how we manage patients with neovascular AMD, diabetic macular edema, and retinal vein occlusion.

This continuing education activity is provided by Vindico Medical Education and is supported by an independent medical education grant from Regeneron Pharmaceuticals.